Sharekhan

Alembic Pharmaceuticals Ltd

Thu 13/03/2025,15:59:6 NSE: APLLTD

₹ 827.35 21.45 (2.66%)
BUY NOW Buy Alembic Pharmaceuticals Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Alembic Pharmaceuticals Ltd

Thu 13/03/2025,0:0:0

Alembic Pharmaceuticals Ltd

Thu 13/03/2025,15:59:6 | NSE : APLLTD

₹ 827.3521.45 (2.66%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 813.20

Previous Close

₹ 805.90

Volume

120379

Mkt Cap ( Rs. Cr)

₹16262.65

High

₹ 836.00

Low

₹ 800.25

52 Week High

₹ 1303.90

52 Week Low

₹ 725.20

Book Value Per Share

₹ 248.68

Dividend Yield

1.32

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Alembic Pharmaceuticals Ltd

Your Vote -

Buy

68.15%

Hold

15.92%

Sell

15.92%

68.15%

157 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

827.35

16

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

16

Option Chain

Analyzes market sentiment, predicts Alembic Pharmaceuticals Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Alembic Pharma’s Vadodara Bioequivalence facility completes USFDA inspection

    7 Mar 2025, 4:48PM Alembic Pharmaceuticals Limited has announced the successful completion of a scheduled inspection by the United States Food and Drug Administration (U

  • Alembic Pharmaceutic - General Updates

    7 Mar 2025, 4:23PM Alembic Pharmaceuticals Limited has informed the Exchange about General Updates: Completion of USFDA inspection at its Bioequivalence Facility at Vado

  • Alembic Pharmaceutic - Completion Of USFDA Inspection At Alembic Pharmaceuticals Limited'S Bioequivalence Facility At Vadodar

    7 Mar 2025, 4:23PM We would like to inform the exchange that the USFDA has conducted an inspection at our Bioequivalence Facility located at Vadodara from 3rd March, 202

  • Alembic Pharmaceutic - Copy of Newspaper Publication

    6 Mar 2025, 6:43PM Alembic Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication related to notice of loss of equity share certificate.

  • Alembic Pharmaceutic - Analysts/Institutional Investor Meet/Con. Call Updates

    19 Feb 2025, 3:04PM Alembic Pharmaceuticals Limited has informed the Exchange about Schedule of meet

  • Alembic Pharmaceutic - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    19 Feb 2025, 3:03PM Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Analysts / Investors Meeting\r\n

  • Alembic Pharmaceutic - General Updates

    14 Feb 2025, 6:36PM Alembic Pharmaceuticals Limited receives Establishment Inspection Report (EIR) for its Solid Oral Formulation Facility (F-4) at Jarod

  • Alembic Pharmaceutic - Alembic Pharmaceuticals Limited Receives Establishment Inspection Report (EIR) For Its Solid Oral Form

    14 Feb 2025, 6:33PM We would like to inform the Exchange that the Company has received an Establishment Inspection Report (EIR) today with classification as \Voluntary Ac

  • Alembic Pharmaceutic - Copy of Newspaper Publication

    13 Feb 2025, 6:44PM Alembic Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication of Postal Ballot Notice.

  • Alembic Pharmaceutic - Notice Of Shareholders Meetings-XBRL

    12 Feb 2025, 3:41PM Alembic Pharmaceuticals Limited has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot

  • Alembic Pharmaceutic - Shareholders meeting

    12 Feb 2025, 3:39PM Alembic Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot

  • Alembic Pharmaceutic - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    12 Feb 2025, 3:36PM Please find attached herewith the Postal Ballot Notice dated 3rd February, 2025.

  • Alembic Pharmaceutic - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    11 Feb 2025, 5:25PM ALEMBIC PHARMACEUTICALS LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Tran

  • Alembic Pharmaceutic - Change in Management

    11 Feb 2025, 5:22PM Alembic Pharmaceuticals Limited has informed the Exchange about change in Senior Management Personnel

  • Alembic Pharmaceutic - General Updates

    11 Feb 2025, 5:17PM Alembic Pharmaceuticals Limited has informed the Exchange about General Updates:The Company has received an Order from Office of the Assistant Commiss

  • Alembic Pharmaceutic - Announcement under Regulation 30 (LODR)-Change in Management

    11 Feb 2025, 5:21PM Intimation under Regulation 30 of SEBI LODR Regulations, 2015 - Change in Senior Managerial Personnel

  • Alembic Pharmaceutic - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations,

    11 Feb 2025, 5:13PM The Company has received an Order from Office of the Assistant Commissioner - Patna.

  • Alembic Pharmaceutic - Analysts/Institutional Investor Meet/Con. Call Updates

    10 Feb 2025, 4:42PM Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Analysts / Investors Meeting

  • Alembic Pharmaceutic - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    10 Feb 2025, 4:39PM Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Analysts / Investors Meeting\r\n

  • Alembic Pharmaceutic - Copy of Newspaper Publication

    4 Feb 2025, 4:48PM Alembic Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication of the Unaudited Financial results for the quarter ended

  • Alembic Pharmaceutic - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    4 Feb 2025, 10:33AM ALEMBIC PHARMACEUTICALS LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Tran

  • Alembic Pharmaceutic - Retirement

    4 Feb 2025, 10:02AM Alembic Pharmaceuticals Limited has informed the Exchange about Retirement-Completion of tenure of Dr. Archana Hingorani as an Independent Director of

  • Alembic Pharmaceutic - Announcement under Regulation 30 (LODR)-Retirement

    4 Feb 2025, 10:02AM The exchange is been informed about the completion of Tenure of Dr. Archana Hingorani as an Independent Director of the Company.

  • Alembic Pharmaceutic - Integrated Filing- Financial

    3 Feb 2025, 4:13PM Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No.

  • Alembic Pharmaceutic - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    3 Feb 2025, 3:47PM ALEMBIC PHARMACEUTICALS LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Tran

  • Alembic Pharmaceutic - Appointment

    3 Feb 2025, 2:53PM Alembic Pharmaceuticals Limited has informed the Exchange regarding Appointment of Mrs. Geeta Goradia as Non- Executive Independent Director of the co

  • Alembic Pharmaceutic - Investor Presentation

    3 Feb 2025, 2:45PM Alembic Pharmaceuticals Limited has informed the Exchange about Investor Presentation

  • Alembic Pharmaceutic - Press Release

    3 Feb 2025, 2:41PM Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 03, 2025, titled ""Press Release on the Unaudited F

  • Alembic Pharmaceutic - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    3 Feb 2025, 2:41PM Please find attached the Press release

  • Alembic Pharmaceutic - Financial Result Updates

    3 Feb 2025, 2:35PM Alembic Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.

  • Alembic Pharmaceutic - Outcome of Board Meeting

    3 Feb 2025, 2:33PM Alembic Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on February 03, 2025.

  • Alembic Pharmaceutic - Board Meeting Outcome for Outcome Of The Board Meeting

    3 Feb 2025, 2:33PM Please find the outcome of the meeting.

  • Alembic Pharmaceutic - Integrated Filing (Financial)

    3 Feb 2025, 4:12PM Please find attached the integrated filing for the quarter ended 31st December, 2024

  • Alembic Pharmaceutic Q3 net profit down 63.21% at Rs 85.81 cr

    3 Feb 2025, 3:21PM The company reported standalone net profit of Rs 85.81 crore for the quarter ended December 31, 2024 as compared to Rs 233.24 crore in the same period

  • Alembic Pharmaceutic - Announcement under Regulation 30 (LODR)-Change in Directorate

    3 Feb 2025, 2:52PM Please find attached the intimation for appointment of Ms. Geeta Goradia as independent Director of the Company\r\n\r\n

  • Alembic Pharmaceutic - Announcement under Regulation 30 (LODR)-Investor Presentation

    3 Feb 2025, 2:43PM Please find attached the Investor Presentation.

  • Alembic Pharmaceutic - Results For The Quarter And Nine Months Ended 31St December, 2024

    3 Feb 2025, 2:38PM Results for the quarter and nine months ended 31st December, 2024

  • Alembic Pharmaceutic - Copy of Newspaper Publication

    24 Jan 2025, 4:52PM Alembic Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication; claim of Shares from Company's Unclaimed Suspense Accou

  • Alembic Pharmaceutic - Board Meeting Intimation

    22 Jan 2025, 4:55PM Alembic Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 03-Feb-2025 to consider and approve the Quarterly Unaudite

  • Alembic Pharmaceutic - Board Meeting Intimation for Considering Unaudited Financial Results For The Quarter And Nine Months E

    22 Jan 2025, 4:51PM ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2025 ,inter alia, to cons

  • Alembic Pharmaceutic has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024

    20 Jan 2025, 4:50PM As of December 2024, 69.61% is owned by Promoters and 30.39% by Public. <p align=justify> Among Promoters holding, Indian Promoters holds 69.10% and F

  • Alembic Pharmaceutic - Press Release

    15 Jan 2025, 12:25PM Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 15, 2025, titled ""Alembic Pharmaceuticals receives

  • Alembic Pharmaceutic - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    15 Jan 2025, 12:22PM Alembic Pharmaceuticals receives USFDA Final Approval for Brexpiprazole Tablets, 0.25mg, 0.5 mg, 1 mg, 2 mg, 3mg and 4 mg.

  • Alembic Pharmaceutic - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    6 Jan 2025, 8:37PM ALEMBIC PHARMACEUTICALS LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Tran

  • Alembic Pharmaceutic - Resignation

    6 Jan 2025, 8:36PM Alembic Pharmaceuticals Limited has informed the Exchange regarding Resignation of Mr Vimal Wahi as Other of the company w.e.f. January 01, 2025.

  • Alembic Pharmaceutic - Announcement under Regulation 30 (LODR)-Change in Management

    6 Jan 2025, 8:21PM Please find attached herewith the Intimation for change in SMP

  • Alembic Pharmaceutic - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    6 Jan 2025, 1:23PM Alembic Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  • Alembic Pharmaceutic - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    1 Jan 2025, 3:58PM ALEMBIC PHARMACEUTICALS LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Tran

  • Alembic Pharmaceutic - Change in Management

    1 Jan 2025, 3:54PM Alembic Pharmaceuticals Limited has informed the Exchange about change in Management

  • Alembic Pharmaceutic - Updates

    1 Jan 2025, 3:42PM Alembic Pharmaceuticals Limited has informed the Exchange regarding 'Intimation for change of name of Registrar and Share Transfer Agent ( RTA ) of th

  • Alembic Pharmaceutic - Intimation For Change Of Name Of Registrar And Share Transfer Agent ('RTA') Of The Company

    1 Jan 2025, 3:42PM Please find attached herewith the Intimation for change of name of RTA of the Company from \Linkintime India Private Limited\ to \MUFG Intime India P

  • Alembic Pharmaceutic - Announcement under Regulation 30 (LODR)-Change in Management

    1 Jan 2025, 3:55PM Please find attached herewith the Intimation under Regulation 30 of SEBI LODR, Regulations, 2015 - Appointment of Senior Management Personnel.

  • Alembic Pharmaceutic - Trading Window-XBRL

    27 Dec 2024, 5:05PM Alembic Pharmaceuticals Limited has informed the Exchange about Closure of Trading Window

  • Alembic Pharmaceutic - Trading Window

    27 Dec 2024, 4:36PM Alembic Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regul

  • Alembic Pharmaceuticals gets USFDA nod for generic anti-epileptic drug

    20 Dec 2024, 4:50PM Alembic Pharmaceuticals Ltd on Friday said it has received final approval from the US health regulator for its generic Divalproex Sodium delayed-relea

  • Alembic Pharmaceutic - Press Release

    20 Dec 2024, 1:04PM Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 20, 2024, titled ""Alembic Pharmaceuticals receives

  • Alembic Pharmaceutic - Giving guarantees/indemnity/ becoming a surety for third party

    17 Dec 2024, 7:58PM Alembic Pharmaceuticals Limited has informed the Exchange about Giving guarantees/indemnity/ becoming a surety for third party

  • Alembic Pharma receives USFDA approval for Brexpiprazole tablets

    15 Jan 2025 , 1:02PM Brexpiprazole is used to treat symptoms of schizophrenia

  • Alembic Pharma gets USFDA nod for Divalproex Sodium Delayed Release Capsules

    20 Dec 2024 , 2:08PM Divalproex sodium is used to treat certain types of seizures (Epilepsy)

  • Alembic Pharma gets USFDA nod for Olopatadine Hydrochloride Ophthalmic Solution.

    4 Dec 2024 , 1:43PM Olopatadine Hydrochloride Ophthalmic Solution use to temporarily relieve itchy eyes

  • Alembic Pharmaceuticals

    21 Oct 2024 , 11:39AM Company receives USFDA approval for Diltiazem Hydrochloride extended-release capsules used for the treatment of high blood pressure & prevents chest pain

  • Alembic Pharma gets final USFDA nod for alcaftadine ophthalmic solution

    4 Oct 2024 , 10:49AM Alcaftadine Ophthalmic Solution is used to temporarily relieve itchy eyes

  • Alembic Pharmaceuticals

    6 Sep 2024 , 10:07AM Company gets final USFDA nod for Albendazole Tablets, indicated for the treatment of Parenchymal Neurocysticercosis (Positive)

  • Alembic Pharmaceuticals

    26 Aug 2024 , 9:41AM Alembic Pharma announced that it has received final approval from the US Food & Drug Administration for its Abbreviated New Drug Application (ANDA) Betamethasone Valerate Foam, 0.12%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Luxiq Foam, 0.12%, of Norvium Bioscience, LLC (Norvium). Betamethasone valerate foam, 0.12% is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. (Positive)

  • Alembic Pharma gets final USFDA nod for Dabigatran Etexilate Capsules

    13 Aug 2024 , 12:55PM Alembic Pharmaceuticals receives USFDA Final Approval for Dabigatran Etexilate Capsules 110 mg

  • Alembic Pharma

    15 Jul 2024 , 11:01AM Alembic Pharmaceuticals receives USFDA Tentative Approval for Selexipag for Injection, 1,800 mcg/vial. The approved ANDA is therapeutically equivalent to the reference listed drug product, Uptravi for Injection, 1,800 mcg/vial, of Actelion Pharmaceuticals US, Inc. (Positive)

  • Alembic Pharmaceuticals

    10 Jul 2024 , 10:27AM The company announced that it has received final approval from the US Food & Drug Administration (US FDA) for its abbreviated new drug application(ANDA) for Bromfenac Ophthalmic Solution, 0.07 per cent. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Prolensa Ophthalmic Solution, 0.07 per cent, of Bausch & Lomb Incorporated. Positive

  • Alembic Pharma gets tentative USFDA nod for Ivosidenib Tablets

    4 Jul 2024 , 1:29PM Ivosidenib Tablet is used to treat certain type of Acute Myeloid Leukemia

  • Alembic Pharmaceuticals gets USFDA nod for Sacubitril and Valsartan Tablets.

    30 May 2024 , 1:26PM Sacubitril and Valsartan Tablets use to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients

  • Alembic Pharma's Vadodara unit receives an establishment inspection report from USFDA

    10 May 2023 , 10:22AM Alembic Pharma gets EIR for its Solid Oral Formulation Facility (F-4) at Jarod

  • Alembic Pharmaceuticals

    10 Mar 2023 , 10:57AM Alembic Pharmaceuticals has received an approval from the USFDA to market Brexpiprazole tablets, which is therapeutically equivalent to Otsuka Pharmaceutical Co's reference listed drug (RLD) Rexulti tablets. Brexpiprazole tablets are indicated as an adjunctive therapy to antidepressants for the treatment of major depressive disorder and for the treatment of schizophrenia. According to IQVIA data, Brexpiprazole tablets have an estimated market size of USD 1.6 billion for 12 months ended December 2022. Positive read through for the stock.

  • Alembic Pharma receives tentative USFDA approval for antidepressant tablets

    9 Mar 2023 , 1:31PM Brexpiprazole Tablets use for the treatment of major depressive disorder and for treatment of schizophrenia

  • Alembic Pharma

    9 Mar 2023 , 10:17AM Alembic Pharma has received final approval from the USFDA for its ANDA for Prazosin Hydrochloride Capsules to treat hypertension. It is therapeutically equivalent to Minipress capsules of Pfizer Inc. Prazosin Hydrochloride Capsules USP, 1 mg, 2 mg, and 5 mg have an estimated market size of USD 50 million for 12 months ended December 2022, according to IQVIA. Minipress capsules are already being produced generically by 6 players including Granules India. Marginally positive read through for the stock. We do not have coverage on it.

  • Alembic Pharma gets USFDA approval for Prazosin Hydrochloride Capsules

    8 Mar 2023 , 10:07AM Alembic Pharmaceuticals announces USFDA Final Approval for Prazosin Hydrochloride Capsules USP

  • Alembic Pharma gets USFDA approval for colon cancer injection

    6 Mar 2023 , 12:43PM Alembic Pharmaceuticals gets final nod from the USFDA for its Abbreviated New Drug Application (ANDA) Fluorouracil Injection

  • Alembic Pharmaceuticals

    3 Mar 2023 , 10:55AM The company will take an impairment charge of Rs 1,150 crore on three manufacturing facilities under construction in Gujarat. The three plants are expected to take a hit to their profitability and generate less cash than expected. Negative read through for the stock. We do not have it in coverage.

  • Alembic Pharmaceuticals

    3 Mar 2023 , 10:54AM The company will take an impairment charge of Rs 1,150 crore on three manufacturing facilities under construction in Gujarat. The three plants are expected to take a hit to their profitability and generate less cash than expected. Negative read through for the stock. We do not have it in coverage.

  • Alembic Pharmaceutical

    2 Mar 2023 , 10:51AM Alembic Pharmaceuticals said it has received approval from the US health regulator to market a generic breast cancer drug. The company has received final approval from the US Food & Drug Administration (USFDA) to market Docetaxel Injection in multiple dose vials. The company's approved product is therapeutically equivalent to Hospira Inc's drug. Docetaxel Injections are indicated for breast cancer, non-small cell lung cancer, castration-resistant prostate cancer, gastric adenocarcinoma and squamous cell carcinoma of head and neck. According to IQVIA data, Docetaxel injection has an estimated market size of USD 11 million in the US market. Positive read through for the stock. We do not have coverage on it.

  • Alembic Pharma gets final USFDA nod for Docetaxel Injection USP

    1 Mar 2023 , 12:07PM Docetaxel Injection is used in the treatment of certain types of cancer

  • Alembic Pharma gets tentative USFDA nod for Acalabrutinib Capsules

    19 Jan 2023 , 1:31PM Acalabrutinib Capsules are used to treat people with mantle cell Lymphoma

  • Alembic Pharma gets USFDA final nod for Fesoterodine Fumarate Extended-Release tablets

    6 Jan 2023 , 10:55AM Fesoterodine Fumarate is used to treat bladder problems

  • Alembic Pharma

    26 Dec 2022 , 11:24AM Alembic Pharmaceuticals Limited (Alembic) announced that it has received final approval from the USFDA for its ANDA, Fulvestrant Injection 250 mg/ 5 ml per single dose prefilled syringe. The approved ANDA is equivalent to its reference listed drug (RLD) Fasoldex injection 250 mg / 5 ml of AstraZeneca Pharmaceutical LP. The injection is an estrogen receptor antagonist indicated for the treatment of breast cancer. Fulvestrant has an estimated market size of USD 71 million for LTM ended Sep 22 according to IQVIA.

  • Alembic Pharma gets USFDA final nod for Fulvestrant Injection

    26 Dec 2022 , 10:07AM Alembic Pharma gets final US FDA nod for Fulvestrant Injection used to treat breast cancer

  • Alembic Pharma gets final USFDA nod for Desonide Cream

    9 Dec 2022 , 10:57AM Alembic Pharmaceuticals receives USFDA Final Approval for Desonide Cream, 0.05%.

  • Alembic Pharma gets final USFDA nod for Diclofenac Sodium Topical Solution

    1 Dec 2022 , 11:14AM Diclofenac Sodium Topical Solution is used to relieve pain from Arthritis

  • Alembic Pharma

    15 Nov 2022 , 10:02AM The company has received approval from the US health regulator to market Cyclophosphamide capsules, used in the treatment of different kinds of cancers in the American market. The approved ANDA is therapeutically equivalent to the reference list drug product (RLD), Cyclophosphamide Capsules 25mg, and 50mg of Hikma Pharmaceuticals USA Inc. The product has a estimated market size US$ 8 million for twelve months for ending Sept 2022 according to IQVIA. Alembic has cumulative total of 176 ANDA approvals (152 final approval and 24 tentative approvals) from the USFDA

  • Alembic Pharmaceuticals receives USFDA approval for Cyclophosphamide Capsules

    14 Nov 2022 , 9:43AM Alembic Pharmaceuticals gets final nod from USFDA for its ANDA for Cyclophosphamide Capsules

  • Alembic Pharmaceuticals gets USFDA final nod for Chlorthalidone Tablets USP

    29 Aug 2022 , 11:40AM Alembic Pharmaceuticals receives final approval from the USFDA for its ANDA for Chlorthalidone Tablets USP, 25 mg and 50 mg

  • Alembic Pharma gets USFDA nod for Adapalene and Benzoyl Peroxide Topical Gel

    8 Aug 2022 , 10:38AM Adapalene & BenzoyI Peroxide Topical Gel treats acne vulgaris

  • Alembic Pharma gets USFDA nod for Diclofenac Sodium Topical Gel

    29 Jul 2022 , 11:09AM Diclofenac Sodium Topical Gel is used to treat pain caused by osteoarthritis of the knees

  • Alembic Pharmaceuticals

    10 Jun 2022 , 11:55AM Gets tentative approval from the USFDA for its ANDA for Dasatinib Tablets strength - 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg. The tablets is indicated for the treatment of adult patients with chronic myeloid leukemia (CML). Dasatinib Tablets have an estimated market size of $1.46 bn in the US as of twelve months ending December 2021. Considering the substantial addressable market size the receipt of tentative approval is positive

  • Alembic Pharmaceuticals receives USFDA Tentative Approval for Dasatinib Tablets

    10 Jun 2022 , 11:45AM Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg

  • Alembic Pharmaceuticals

    24 May 2022 , 11:31AM Alembic Pharmaceutical: Gets final USFDA approval for its ANDA - Pirfenidone Tablets in strengths of - 267 mg and 801 mg. Pirfenidone Tablets are indicated for the treatment of idiopathic pulmonary fibrosis and the estimated market size fo the tablet in the US markets is $548 mn for the 12 months ending December 2021. Considering the sizeable addressable market size, the approval is positive

  • Alembic Pharma gets final USFDA nod for Pirfenidone tablets

    24 May 2022 , 10:51AM Alembic Pharmaceuticals receives USFDA Final Approval for Pirfenidone Tablets, 267 mg a~d 801 mg.

  • Alembic Pharma receives final USFDA nod for Arformoterol Tartrate inhalation solution

    11 May 2022 , 11:29AM Arformoterol Tartrate Inhalation Solution is used to treat breathing problems

  • Alembic Pharma arm gets USFDA final nod for Clobetasol Propionate Foam

    25 Apr 2022 , 11:12AM Clobetasol Propionate Foam is for treatment of the scalp and mild to moderate plaque psoriasis of non-scalp regions of the body

  • Alembic gets USFDA nod to market generic drug

    20 Apr 2022 , 1:37PM Approved lvabradine tablets are used to treat heart failure

  • Alembic Pharma arm get USFDA final nod for Lidocaine & Prilocaine cream USP

    12 Apr 2022 , 10:04AM Alembic Pharmaceuticals' wholly owned subsidiary, Aleor Dermaceuticals gets USFDA final approval for Lidocaine and Prilocaine Cream USP

  • Alembic Pharma gets tentative USFDA nod for Dabigatran Etexilate Capsules

    7 Apr 2022 , 12:01PM Alembic Pharma gets tentative USFDA nod for Dabigatran Etexilate Capsules, used for treatment of deep venous thrombosis & pulmonary embolism

  • Alembic Pharma to acquire 40% stake held by Orbicular Pharma

    29 Mar 2022 , 2:15PM Alembic Pharma to acquire 40% stake held by Orbicular Pharma in company’s joint venture Aleor Derma

  • Alembic Pharma

    21 Mar 2022 , 1:50PM Alembic Pharma: Gets USFDA final approval for its ANDA for Lacosamide Tablets USP strengths - 50 mg, 100 mg, 150 mg, and 200 mg (Reference listed drug (RLD) – Vimpat Tablets). Lacosamide Tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older. The tablets have an estimated market size of US$ 1.67 billion for twelve months ending December 2021. Given the substantial addressable market size, the approval is positive and could would aid US sales growth.

  • Alembic Pharma gets final USFDA nod for Lacosamide Tablets USP

    21 Mar 2022 , 1:18PM Alembic Pharmaceuticals receives USFDA Final Approval for Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg, and 200 mg

  • Alembic Pharmaceuticals receives USFDA tentative approval for Macitentan Tablets

    14 Mar 2022 , 11:51AM Macitentan is an endothelin receptor antagonist, indicated for the treatment of pulmonary arterial hypertension

  • Alembic Pharma’s JV, Aleor Derma gets USFDA nod for Ointment

    8 Mar 2022 , 11:44AM Alembic Pharma’s JV, Aleor Derma gets USFDA final approval for Nystatin & Triamcinolone Acetonide Ointment, indicated for the treatment of cutaneous candidiasis

  • Q3FY2022 Results - Alembic Pharmaceuticals

    11 Feb 2022 , 12:42PM Viewpoint Q3FY2022 Results - Alembic Pharmaceuticals

  • Alembic Pharmaceuticals

    2 Feb 2022 , 2:01PM Alembic Pharmaceuticals: Gets USFDA tentative approval for ANDA - Fesoterodine Fumarate Extended Release Tablets strength- 4 mg and 8 mg. The tablets are indicated for r the treatment of overactive bladder in adults. Fesoterodine Furnarate Extended-Release Tablets have an estimated market size of US$ 225mn as of 12 months ending September 2021. Considering the strong addressable market size the tentative approval is positive.

  • Alembic Pharma gets tentative USFDA nod for Fesoterodine Fumarate Tablets

    2 Feb 2022 , 11:14AM Alembic Pharmaceuticals receives USFDA tentative approval for Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg

  • Alembic Pharmaceuticals

    2 Feb 2022 , 10:36AM Alembic Pharmaceuticals: Gets USFDA final approval for Clarithromycin Tablets USP Strength - 250 mg and 500 mg. Clarithromycin Tablets are indicated for mild to moderate infections of chronic bronchitis in adults; acute maxillary sinusitis; community-acquired pneumonia; pharyngitis/tonsillitis. Clarithromycin Tablets USP have an estimated market size of US$ 11 mn as at 12 months ending September 2021. Considering the material addressable market opportunity, the approval is positive

  • Alembic Pharma receives USFDA tentative nod for Dronedarone Tablets

    10 Jan 2022 , 12:49PM Alembic Pharma gets tentative nod from USFDA for dronedarone tablets, used to treat people with heart problems

  • Alembic Pharma receives USFDA tentative nod for Dronedarone Tablets

    10 Jan 2022 , 11:45AM Alembic Pharma gets tentative nod from USFDA for dronedarone tablets, used to treat people with heart problems

  • Viewpoint - Alembic Pharmaceuticals

    10 Jan 2022 , 11:10AM Viewpoint - Alembic Pharmaceuticals: Getting on the growth path

  • Viewpoint - Alembic Pharmaceuticals

    10 Jan 2022 , 11:02AM Viewpoint - Alembic Pharmaceuticals: Getting on the growth path

  • Alembic Pharma

    7 Jan 2022 , 10:58AM Alembic Pharma: gets USFDA approval for its ANDA - Entacapone Tablets USP, 200 mg, which are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose "wearing-off" in patients with Parkinson's disease. Entacapone Tablets have an estimated market size of US$ 10.5 million for twelve months ending September 2021. Positive read thru

  • Alembic Pharma gets US regulator's nod for anti-Parkinson's drug

    6 Jan 2022 , 1:19PM Alembic Pharma gets USFDA nod for anti-Parkinson's drug, Entacapone tablet

  • Alembic Pharmaceuticals gets USFDA nod for antibiotic drug

    4 Jan 2022 , 12:25PM Alembic Pharmaceuticals receives USFDA Final Approval for Doxycycline Hyclate Delayed-Release Tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg

  • Alembic Pharma

    17 Dec 2021 , 11:33AM As per media news the company’s Gujarat plant has received a Form 483 with 10 observations, including one repeat observations after it was inspected by the USFDA in October 28-November 10. The USFDA observations point that the plant had not established control procedures and processes with respect to cleaning and maintenance were inadequate. The facility is a fairly new sterile injectables facility and the resolution could take some time. Currently the company has 10 fillings from this plant. Negative read thru though we currently do not have a recommendation on the stock

  • Alembic Pharmaceuticals

    13 Dec 2021 , 10:30AM Alembic Pharmaceuticals: Has acquired a preferred stock in US based start up biopharmaceutical Research Company – RIGlmmune focused on the development of RNA based therapies for viral diseases and oncology applications. RIGImmune was founded in 2020 by two professors from the Yale university - Dr. Anna Pyle and Dr. Akiko Iwasaki. Alembic has acquired a preferred stock amounting to 19.97% post money stake in the first closing of the series seed round. The acquisition would enable Alembic to enter in to drug development – development of New Chemical Entity, which is a niche segment so, Potential Positive for Alembic. We do not have any coverage on the stock.

  • Alembic Pharma

    9 Dec 2021 , 9:43AM The company has received a tentative approval from the USFDA for its ANDA for Selexipag Tablets, 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,400 mcg, and 1,600 mcg. Selexipag Tablets are indicated for the treatment of pulmonary arterial hypertension to delay disease progression and reduce the risk of hospitalization. The drug has an estimated market size of US$ 461 million for twelve months ending September 2021 according to IQVIA. Given the substantial addressable market size, the tentative approval is positive.

  • Alembic Pharma gets tentative USFDA nod for Hypertension drug

    8 Dec 2021 , 11:47AM Alembic Pharmaceuticals receives USFDA Tentative Approval for Selexipag Tablets

  • Alembic Pharma gets tentative USFDA nod for Dabigatran Etexilate Capsules

    23 Nov 2021 , 11:54AM Dabigatran Etexilate is used to treat patients with Non-Valvular Atrial Fibrillation

  • Alembic Pharma gets USFDA nod for formoterol Fumarate Inhalation Solution

    23 Nov 2021 , 11:19AM Alembic Pharma receives final USFDA nod for formoterol Fumarate Inhalation Solution, used to treat chronic lung disease in adults

  • Alembic Pharma JV Aleor Derma gets USFDA nod for Mupirocin Cream

    17 Nov 2021 , 12:19PM Alembic Pharma JV Aleor Derma gets USFDA nod for Mupirocin Cream, used for treatment of traumatic skin lesions

  • Alembic Pharmaceuticals

    11 Nov 2021 , 9:41AM Alembic Pharma: The USFDA has inspected the company’s Karkhadi facility between 28th October, 2021 ta. 10th November, 2021. The inspection ended with a form 483 with 10 observations and none of the observations relate to data integrity issues. The management would be submitting its responses to the USFDA for the observations, however the receipt of the form 483 with 10 observations is negative

  • Alembic Pharma's JV Aleor Derma gets US FDA nod for Metronidazole Gel USP

    6 Sep 2021 , 12:38PM Alembic Pharma’s JV Aleor Derma gets US FDA nod for Metronidazole Gel USP, used to treat skin infections, rosacea and mouth infections

  • Alembic Pharma gets final USFDA nod for Clomipramine Hydrochloride Capsules

    5 Aug 2021 , 11:40AM Alembic Pharma gets final USFDA nod for Clomipramine Hydrochloride Capsules, used for treatment of obsessive-compulsive disorder (OCD)

  • Alembic Pharmaceuticals

    9 Jul 2021 , 1:50PM Gets final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Erlotinib Tablets, 25 mg, 100 mg, and 150 mg. Erlotinib Tablet in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer. Erlotinib tablets have an estimated market size of US$ 37 million for twelve months ending March 2021 according to IQVIA. The approval is positive and would add to the US business growth.

  • Alembic Pharmaceuticals announces USFDA final approval for Erlotinib Tablets

    9 Jul 2021 , 12:11PM Alembic Pharma receives USFDA final approval for Erlotinib tablets, used for treatment of metastatic non-small cell lung cancer

  • Alembic Pharma gets USFDA nod for antidepressant drug

    8 Jul 2021 , 11:05AM Desipramine Hydrochloride Tablets, USP are indicated for the treatment of depression

  • Alembic Pharma gets USFDA nod for generic of Nitrofurantoin Capsules

    1 Jul 2021 , 12:45PM Alembic Pharma gets USFDA approval for Nitrofurantoin Capsules, indicate for treatment of urinary tract infections

  • Alembic Pharma's JV Aleor Dermaceuticals gets USFDA final nod

    16 Jun 2021 , 11:44AM Alembic Pharma's JV Aleor Dermaceuticals gets USFDA final nod for Testosterone Topical Solution USP, 30 mg per pump actuation

  • Alembic Pharma gets USFDA final nod for Lurasidone Hydrochloride Tablets

    14 May 2021 , 11:37AM Alembic Pharmaceuticals announces USFDA Final Approval for Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg

  • Alembic Pharma gets final nod from USFDA

    5 May 2021 , 11:15AM Alembic Pharma gets USFDA nod for for Dorzolamide HCL & Timolol Maleate Ophthalmic Soln

  • Alembic Pharma gets USFDA nod for Doxepin Hydrochloride Capsules

    23 Apr 2021 , 10:59AM Alembic Pharmaceuticals receives USFDA final nod for Doxepin Hydrochloride Capsules

  • Alembic Pharma’s JV Aleor Derma gets tentative US FDA nod

    8 Apr 2021 , 11:55AM Alembic Pharma announces its JV Aleor Dermaceuticals receives USFDA tentative nod for Efinaconazole Topical Solution

  • Alembic Pharma's JV Aleor Derma gets USFDA nod for Testosterone Gel

    4 Mar 2021 , 11:16AM Alembic Pharma's JV Aleor Derma gets US FDA nod for testosterone gel indicates for replacement therapy

  • Alembic Pharmaceuticals

    18 Feb 2021 , 9:11AM As per media news, USFDA has found issues related to quality control, cleanliness and size of equipment and inadequate sample collection procedures at Alembic Pharmaceuticals’ new sterile Injectables unit in Karkhadi unit in Gujarat. The regulator earlier had issued a form 483 with 5 observations. This is points towards a possible delay for new product launches from the plant and hence is negative

  • Alembic Pharma arm gets USFDA nod Treprostinil Injection

    12 Feb 2021 , 2:07PM Alembic Pharmaceuticals' arm Alembic Global receives USFDA approval for Treprostinil Injection

  • Alembic Pharma's unit gets five observations from USFDA

    8 Feb 2021 , 12:40PM USFDA inspection at Alembic Pharmaceuticals new injectable facility (F-3) at Karkhadi

  • Alembic Pharma gets USFDA nod for Midodrine Hydrochloride Tablets

    22 Jan 2021 , 12:26PM Midodrine Hydrochloride Tablets used for treatment of symptomatic orthostatic hypotension

  • Alembic Pharma gets USFDA nod for Asenapine Sublingual Tablets

    11 Dec 2020 , 9:54AM Alembic Pharmaceuticals receives USFDA final approval for Asenapine Sublingual Tablets, 5 mg and 10 mg

  • Alembic Pharma gets USFDA nod for Metolazone Tablets

    3 Dec 2020 , 11:39AM Alembic Pharma gets USFDA nod for Metolazone Tablets, used to reduce swelling & fluid retention caused by heart failure or kidney disease

  • Alembic Pharma gets USFDA approval for testosterone gel

    25 Nov 2020 , 12:39PM Alembic Pharma announces that its JV, Aleor Dermaceuticals, gets US drug regulator's tentative approval for testosterone gel

  • Alembic Pharma gets final nod from USFDA

    26 Oct 2020 , 9:34AM Alembic Pharma gets USDA nod for Timolol Maleate Ophthalmic Gel which is used to treat increased pressure inside the eye

  • Alembic Pharmaceuticals gets USFDA final nod for Fenofibrate Capsules

    21 Oct 2020 , 11:01AM Fenofibrate Capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients

  • Alembic Pharma gets USFDA nod for Amantadine Hydrochloride Tablets, 100 mg.

    16 Oct 2020 , 11:40AM Amantadine Hydrochloride tablets are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus

  • Alembic Pharma enters into agreement with Curon Biopharma

    13 Oct 2020 , 10:39AM Alembic Pharma's associate company enters into an exclusive license agreement with Curon Biopharmaceutical

  • Alembic Pharmaceuticals gets USFDA Tentative nod for Treprostinil Injection

    7 Sep 2020 , 2:42PM Alembic Pharmaceuticals receives USFDA Tentative Approval for Treprostinil Injection

  • Alembic Pharma receives USFDA approval for Desonide lotion

    25 Aug 2020 , 12:06PM Aleor Dermaceuticals receives USFDA final approval for Desonide Lotion, 0.05%

  • Alembic Pharma-Aleor JV gets tentative USFDA nod for anti-fungal, Tavaborole topical solution

    13 Aug 2020 , 11:28AM Alembic Pharmaceuticals announces its joint venture, Aleor Dermaceuticals receives USFDA Tentative Approval for Tavaborole Topical Solution

  • Alembic Pharmaceuticals

    7 Aug 2020 , 10:06AM Alembic Pharma: Has raised Rs 750cr through the QIP route . The QIP issue was done at a price of Rs 932 per share, which was at a discount of 4.9% to the floor price and discount of 14% to the closing price on Thursday. Of the proceeds, Rs 400 cr would be utilised towards debt repayment while the balance will be used for expanding API, injectable manufacturing facilities.

  • Alembic Pharma gets USFDA nod for Vardenafil Hydrochloride Tablets

    5 Aug 2020 , 10:48AM Alembic Pharma gets USFDA nod for vardenafil hydrochloride tablets. Do not, vardenafil is used to treat erectile dysfunction

  • Alembic Pharma board approves raising up to Rs. 1,000 cr via QIP

    27 Jul 2020 , 12:42PM Board approves to raise capital up to Rs. 1,000 crore through a Qualified Institutional Placement (QIP)

  • Alembic Pharma gets tentative USFDA nod for Empagliflozin & Metformin Hydrochloride tablets

    20 Jul 2020 , 10:45AM The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product

  • Alembic Pharma gets USFDA nod for Doxycycline Hyclate tablets, used to treat chest infection

    1 Jul 2020 , 10:45AM Alembic Pharmaceuticals receives USFDA Final Approval for Doxycycline Hyclate Tablets USP, 75 mg and 150 mg

  • Alembic Pharmaceuticals

    22 Jun 2020 , 1:33PM Gets tentative approval for its ANDA - Rivaroxaban Tablets, Reference listed drug has estimated market size of $6.1bn; approval is positive considering the substantial size of opportunity

  • Alembic Pharma's JV, Aleor Dermaceuticals receives USFDA final nod for Adapalene Gel USP

    19 Jun 2020 , 11:12AM Alembic Pharmaceuticals announces its joint venture, Aleor Dermaceuticals, receives USFDA Final Approval for Adapalene Gel USP, 0.3%

  • Alembic Pharmaceuticals receives USFDA Final Approval for Deferasirox Tablets

    16 Jun 2020 , 11:18AM Receives final approval from the USFDA for its abbreviated new drug application Deferasirox Tablets

  • Alembic Pharma's JV Aleor Derma gets USFDA nod for Clobetasol Propionate Shampoo

    19 May 2020 , 11:25AM Alembic Pharmaceuticals announces its joint venture, Aleor Dermaceuticals receives USFDA Approval for Clobetasol Propionate Shampoo, 0.05%.

  • Alembic Pharmaceuticals gains after USFDA nod

    15 May 2020 , 12:47PM Alembic Pharmaceuticals announces USFDA Final Approval for Doxycycline Hyclate Tablets USP, 100 mg

  • Alembic Pharmaceuticals JV gets EIR for its Karakhadi formulations facility

    6 May 2020 , 11:51AM Alembic Pharmaceuticals announces its JV, Aleor Dermaceuticals Ltd., receives EIR for its formulation facility at Karkhadi

  • Alembic Pharmaceuticals

    20 Apr 2020 , 10:41AM Gets USFDA tentative approval for its ANDA Alcaftidine Opthalmic solution 0.25%, indicated for prevention of itching associated with conjunctivitis. Positive read thru

  • Alembic Pharma gets USFDA tentative nod for ANDA

    20 Apr 2020 , 9:37AM Alembic Pharmaceuticals receives USFDA Tentative Approval for Alcaftadine Ophthalmic Solution, 0.25%

  • Alembic Pharmaceuticals receives EIR from USFDA

    17 Mar 2020 , 2:10PM Alembic Pharmaceuticals receives EIR for its API facility at Karakhadi

  • USFDA inspects Alembic Pharma's Panelav facility

    16 Mar 2020 , 10:45AM USFDA inspection at Alembic Pharmaceuticals general oral solid formulation facility at panelav

  • Alembic Pharmaceuticals declares dividend

    6 Mar 2020 , 2:44PM Board declares interim dividend of Rs. 10 per equity share

  • Alembic Pharma gets USFDA nod for Doxycycline Hyclate Tablets USP, 20 mg

    5 Mar 2020 , 11:23AM Doxycycline Hyclate Tablets are indicated for use as an adjunct to scaling and root planing

  • Alembic Pharma gets USFDA nod for anti-bacterial drug

    28 Jan 2020 , 10:41AM Alembic Pharmaceuticals announces USFDA Final Approval for Azithromycin Tablets USP, 600 mg.

  • Alembic Pharma gets USFDA nod for anti-bacterial drug

    28 Jan 2020 , 10:40AM Alembic Pharmaceuticals announces USFDA Final Approval for Azithromycin Tablets USP, 600 mg.

  • Alembic Pharma gets USFDA nod for Bosentan Tablets

    24 Jan 2020 , 10:59AM Bosentan Tablets use for the treatment of pulmonary arterial hypertension

  • Alembic Pharma gets USFDA nod for Bimatoprost Ophthalmic Solution

    23 Jan 2020 , 12:20PM Bimatoprost Ophthalmic Solution indicates to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness

  • Alembic Pharma gets two observations for Karkhadi plant

    21 Jan 2020 , 1:28PM USFDA inspection at Alembic Pharmaceuticals API facility at Karkhadi

  • Alembic Pharmaceuticals

    15 Jan 2020 , 1:15PM Has received a tentative approval from the US FDA for its ANDA - Empagliflozin Tablets, 10 mg and 25 mg. Emapgliflozin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It has an estimated market size of USD 3.4 bn for the 12 months ending September 2019 as per IQVIA. The approved ANDA is therapeutically equivalent to the reference listed drug product - Jardiance Tablets of Boehringer lngelheim Pharmaceuticals, Inc. Positive read thru

  • Alembic Pharma gets USFDA tentative nod for Empagliflozin Tablets

    15 Jan 2020 , 12:18PM Emapgliflozin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control

  • Alembic Pharmaceuticals

    15 Jan 2020 , 10:28AM As per media news the company has received an approval from the USFDA for Tizanidine Hydrochloride. Tizanidine is a short-acting muscle relaxer and is used to treat spasticity by temporarily relaxing muscle tone. Positive read thru

  • Alembic Pharma gets USFDA nod for an anti-depression drug

    13 Jan 2020 , 11:10AM Alembic Pharma gets USFDA nod for anti-depression drug, Vilazodone Hydrochloride tablet

  • Alembic Pharma

    9 Jan 2020 , 12:47PM Joint Venture company Aleor received zero observations in an inspection carried out by US FDA for its formulation manufacturing facility in Gujarat.(Inspected from Jan. 6-8). Alembic Pharma has 60% stake in Aleor while the balance is owned by Orbicul. Positive read thru

  • Alembic Pharma up on successful USFDA inspection

    9 Jan 2020 , 10:30AM Successful completion of USFDA inspection at Aleor Dermaceuticals

  • Alembic Pharma gets USFDA nod for a generic of Travatan solution

    24 Dec 2019 , 11:15AM Receives USFDA final nod for Travoprost Ophthalmic Solution USP, a generic of Travatan solution

  • Alembic Pharma, Orbicular Pharma's JV Aleor Derma gets EIR from USFDA

    18 Dec 2019 , 1:56PM Alembic Pharmaceuticals announces its joint venture, Aleor Dermaceuticals received Establishment Inspection Report (EIR) for its Formulation Facility at Karkhadi

  • Alembic Pharma JV gets USFDA nod

    2 Dec 2019 , 11:11AM Alembic Pharma's joint venture, Aleor Dermaceuticals, gets USFDA tentative nod for Diclofenac Sodium Topical Solution USP

  • Alembic Pharmaceuticals gets USFDA nod

    22 Nov 2019 , 1:11PM Alembic Pharma gets USFDA nod for Abbreviated New Drug Applications

  • Alembic Pharma's JV gets USFDA nod for ointment

    24 Oct 2019 , 1:53PM Ointment would reduce swelling, itching caused due to skin conditions

  • Alembic Pharma JV gets USFDA nod Clobetasol Propionate Spray

    4 Oct 2019 , 11:06AM Aleor Dermaceuticals gets USFDA nod for its ANDA Clobetasol Propionate Spray

  • Alembic Pharma JV ges USFDA nod Clobetasol Propionate Spray

    4 Oct 2019 , 11:02AM Aleor Dermaceuticals gets USFDA nod for its ANDA Clobetasol Propionate Spray

  • Alembic Pharma JV ges USFDA nod Clobetasol Propionate Spray

    4 Oct 2019 , 11:02AM Aleor Dermaceuticals gets USFDA nod for its ANDA Clobetasol Propionate Spray

  • Alembic+Pharma+JV+ges+USFDA+nod+Clobetasol+Propionate+Spray

    4 Oct 2019 , 11:05AM Aleor+Dermaceuticals+gets+USFDA+nod+for+its+ANDA+Clobetasol+Propionate+Spray

  • Alembic Pharma gets USFDA nod for Dorzolamide Hydrochloride Ophthalmic Solution

    13 Aug 2019 , 10:14AM Alembic Pharmaceuticals receives approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA)

  • Alembic Pharma gets USFDA nod for Bimatoprost Ophthalmic Solution

    9 Aug 2019 , 12:58PM Alembic Pharmaceuticals receives USFDA Tentative Approval for Bimatoprost Ophthalmic Solution, 0.01 %

  • Alembic Pharmaceuticals gets USFDA tentative nod for Dapagliflozin Tablets

    23 Jul 2019 , 11:58AM Alembic Pharmaceuticals receives USFDA Tentative Approval for Dapagliflozin Tablets, 5 mg and 10 mg

  • Alembic Pharma gets USFDA nod for Clonazepam orally disintegrating tablets

    1 Jul 2019 , 11:31AM Alembic Pharma receives approval from USFDA for Clonazepam Orally Disintegrating tablets which are available in USP

  • Alembic Pharma gets USFDA nod for Oseltamivir Phosphate Capsules USP

    25 Jun 2019 , 11:05AM Alembic Pharmaceuticals receives approval from USFDA for its Abbreviated New Drug Application

  • Alembic Pharmaceuticals gets USFDA nod for Bromfenac Ophthalmic Solution

    24 Jun 2019 , 11:46AM Alembic Pharmaceuticals receives US Food & Drug Administration (USFDA) approval for Bromfenac Ophthalmic solution 0.09%

  • Alembic Pharma raises fund via NCDs

    12 Jun 2019 , 12:10PM Alembic Pharma board approves raising up to Rs 300 cr via Non-convertible debentures

  • Alembic Pharma gets USFDA nod for Carbidopa, levodopa ER tablets

    6 Jun 2019 , 12:53PM Alembic Pharmaceuticals receives USFDA Approval for Carbidopa and Levodopa Extended-Release Tablets USP, 25 mg/100 mg and 50 mg/200 mg

  • Alembic Pharmaceuticals receives USFDA nod for Solifenacin Succinate Tablets

    21 May 2019 , 10:41AM Alembic Pharmaceuticals gets USFDA approval for Solifenacin Succinate Tablets, 5 mg and 10 mg

  • Alembic Pharma-Aleor JV gets EIR from USFDA for Karakhadi unit

    6 May 2019 , 12:20PM USFDA had carried out inspection at Aleor's formulation facility at Karakhadi, Gujarat

  • Alembic Pharma gets USFDA nod for Teriflunomide Tablets

    22 Apr 2019 , 11:15AM Alembic Pharma gets USFDA nod for Teriflunomide Tablets and Tobramycin Ophthalmic Solution

  • Alembic Pharma gets USFDA nod for Bimatoprost Ophthalmic Solution

    15 Apr 2019 , 12:07PM Alembic Pharmaceuticals now has a total of 90 ANDA approvals from USFDA

  • Alembic Pharma gets USFDA nod for Tadalafil tablets

    27 Mar 2019 , 11:08AM Alembic Pharma gets USFDA nod for Tadalafil tablets that is used to treat Erectile Dysfunction

  • Alembic Pharmaceuticals gets USFDA nod for ANDA

    22 Mar 2019 , 11:30AM Alembic Pharmaceuticals receives USFDA Approval for Azelastine Hydrochloride Ophthalmic Solution

  • Alembic Pharma JV Aleor gets FDA nod for Clobetasol Ointment

    5 Mar 2019 , 2:50PM Alembic Pharma JV Aleor Dermaceuticals receives USFDA approval for Clobetasol Propionate Ointment USP, 0.05%

  • Alembic Pharma gets USFDA nod for Acetazolamide Extended-Release Capsules

    20 Feb 2019 , 11:44AM Receives USFDA approval for Acetazolamide Extended-Release Capsules, 500 mg

  • Alembic Pharma gets USFDA for eye drops

    15 Feb 2019 , 11:51AM Alembic Pharma receives USFDA approval for gVigamox eye drops

  • Alembic Pharma gets USFDA approval for Parkinson's drug

    3 Jan 2019 , 11:22AM Alembic Pharmaceuticals gets USFDA nod for Pramipexole Dihydrochloride Extended-Release Tablets

  • Alembic gains after USFDA inspection at Panelav

    20 Dec 2018 , 10:27AM Alembic Pharmaceuticals rises over 4% to Rs. 621.35, after successful USFDA inspection at its API facility at Panelav

  • Alembic Pharma gets USFDA nod for treatment of allergic conjunctiviti's

    10 Dec 2018 , 11:03AM Alembic Pharmaceuticals receives USFDA nod for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1%

  • Alembic Pharma gets USFDA nod for drug to lower blood pressure

    5 Dec 2018 , 11:48AM Alembic Pharmaceuticals receives USFDA approval for Candesartan Cilexetil Tablets USP, 4 mg, 8 mg, and 16 mg

  • Alembic Pharma gets USFDA nod for peptic ulcer drug

    4 Dec 2018 , 11:51AM Alembic Pharma wholly owned subsidiary, Orit Laboratories LLC, receives USFDA nod for Glycopyrrolate Tablets USP, 1 mg and 2 mg

  • Alembic Pharma gets USFDA nod for Diabetes drug

    16 Oct 2018 , 2:35PM Alembic Pharmaceuticals receives USFDA tentative approval for Alogliptin Tablets, 6.25 mg, 12.5 mg and 25 mg

  • Alembic Pharma has 77 ANDA nod from USFDA

    17 Sep 2018 , 1:36PM Alembic Pharmaceuticals receives USFDA Approval for Desvenlafaxine Extended-Release Tablets, 25 mg

  • Alembic Pharma gets USFDA nod for Bimatoprost

    6 Aug 2018 , 12:26PM Alembic Pharma receives tentative approval from USFDA for its ANDA for Bimatoprost ophthalmic solution

  • Alembic Pharma receives EIR for Karakhadi API facility

    20 Jul 2018 , 11:32AM Alembic Pharmaceuticals receive EIR from the US health regulator for its Karakhadi facility in Gujarat

  • Alembic Pharma up 2% on EIR from USFDA

    20 Jul 2018 , 10:22AM Alembic Pharmaceuticals rises over 2% at Rs526.75, after receiving Establishment Inspection Report for its API facility at Karakhadi

  • Alembic Pharma gets USFDA nod for schizophrenia drug

    11 Jul 2018 , 2:17PM Alembic Pharma gets tentative approval from the US health regulator for Iloperidone tablets, used to treat schizophrenia in adults

  • Alembic Pharma gets EIR for Panelav facility

    15 Jun 2018 , 11:45AM Alembic Pharmaceuticals receives Establishment Inspection Report (EIR) for its Formulation Facility at Panelav

  • APL gets USFDA nod for Doxycycline Hyclate capsules

    14 Jun 2018 , 11:52AM Alembic Pharma stock surges by 8% to Rs529.9, after receiving US drug regulator's approval for Doxycycline Hyclate capsules

  • Alembic Pharma gets USFDA nod for anti-depression drug

    11 Jun 2018 , 1:27PM Alembic Pharmaceuticals jumps by 20% at Rs521.8, after it receiving USFDA nod for Bupropion Hydrochloride Tablets in strength of 75 and 100 milligrams

  • Alembic Pharma gets 3 observations for Gujarat plant

    21 Mar 2018 , 2:49PM Alembic Pharma reports that the USFDA has conduct an inspection at Alembic Pharmaceuticals Formulation Facility located at Panelav

  • Alembic Pharma to have a board meeting to consider buyback

    19 Jan 2018 , 1:07PM Stock to remain in focus as Alembic Pharma to have a board meeting on Jan 23, 2018 to consider buyback.

  • Alembic Pharma completes US-based Orit Lab acquisition

    1 Nov 2017 , 11:01AM Alembic Pharma through its subsidiary, has complete the acquisition of USA based generic drug developer, Orit Laboratories LLC

  • Alembic Pharma sell its formulations manufacturing facility at Baddi

    24 Aug 2017 , 2:12PM Alembic Pharma sell its formulations manufacturing facility at Baddi on slump sale basis to Scott Edil Pharmacia

  • Alembic Pharma gains on USFDA nod for new drug

    11 Jul 2017 , 12:15PM Alembic Pharma surges over 5% to Rs545, after receiving tentative approval for its Dabigatran Etexilate Capsules, 150 mg from the USFDA

  • Alembic gets tentative USFDA nod for erectile dysfunction drug

    4 Jul 2017 , 2:32PM Alembic Pharma receives tentative approval from the US health regulator for its ANDA for erectile dysfunction drug

  • Alembic Pharma gets USFDA nod for Candesartan Cilexetil Tablets

    21 Jun 2017 , 1:32PM Alembic Pharma receives US Food & Drug Administration approval for Candesartan Cilexetil Tablets 32mg
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Alembic Pharmaceuticals Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 5328.95 5049.36 5920.33 5454.15 5033.05
Liabilities 5328.95 5049.36 5920.33 5454.15 5033.05
Equity 39.31 39.31 39.31 39.31 37.7
Gross Profit 998.52 664.35 908.8 1572.23 1202.9
Net Profit 666.48 346.73 543.55 1175.39 969.4
Cash From Operating Activities 772.77 730.25 545.26 1485.3 539.75
NPM(%) 11.34 6.73 10.79 23.26 23.45
Revenue 5874.06 5149 5035.41 5051.44 4132.55
Expenses 4875.54 4484.65 4126.61 3479.21 2929.65
ROE(%) 13.63 7.09 11.11 24.04 19.83

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
15 Jul 2024 11 550 1.33 1001.35
17 Aug 2022 10 500 1.33 786.6
19 Jul 2021 14 700 1.33 1006.1
16 Mar 2020 3 150 1.33 661.2
16 Mar 2020 7 350 1.33 656.25
18 Jul 2019 5.5 275 1.33 551.45
18 Jul 2018 4 200 1.33 482.25
11 Jul 2017 4 200 1.33 605.1
20 Jul 2016 4 200 1.33 619.4
22 Jul 2015 3.5 175 1.33 470.75
17 Jul 2014 3 150 1.33 297.25
29 Jul 2013 2.5 125 1.33 117.6
31 Jul 2012 1.4 70 1.33 55.1

Peers

Other companies within the same industry or sector that are comparable to Alembic Pharmaceuticals Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 808.20 -1.14 11.41 472.53 1321.50 1.42
Lotus Eye Hospital and Institute Ltd 57.06 -0.77 237.75 1721.83 14.01 0.88
Vaishali Pharma Ltd 12.12 -5.90 606.00 887.50 2.31 0.00
Astec Lifesciences Ltd 653.90 -5.55 0.00 1623.54 -239.30 0.00

Company Info

2011 Alembic Pharmaceuticals Limited ( the Resulting C ompany ) was originally incorporated on 16th June, 2010 in the name and style 'Alembic Pharma Limited', under the Companies Act, 1956 and had received the Certificate of Commencement of business on 1st July, 2010. The company changed its name from Alembic Pharma Limited to Alembic Pharmaceuticals Limited and the Registrar of Companies, Gujarat has approved the change of name and issued a fresh certificate of incorporation consequent upon change of name on 12th March, 2011. 2012 Alembic and Breckenridge Announce Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiqr). Alembic Pharmaceuticals Limited enters into a product development and license agreement with Accu-Break Pharmaceuticals, Inc, USA. 2013 -Alembic gets USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing agreement with Ranbaxy Pharmaceuticals Inc (Ranbaxy) to market its product in USA. 2014 -"Alembic announces joint venture with Adwiya Mami SARL Algeria through its wholly owned Subsidiary - Alembic Global Holding S.A.". 2015 -Alembic Pharmaceuticals Ltd. arm signs exclusive agreement with Novartis 2016 - Alembic Pharma inks JV agreement with Orbicular Pharma 2017 -Alembic Pharmaceuticals partners with Breckenridge Pharma launching tablets used in the treatment of major depressive disorder. -Alembic Pharma gets USFDA nod for generic antidepressant and anti-hypertension drugs. -Alembic gets FDA tentative nod for erectile dysfunction drug. -Alembic Pharma gets USFDA nod for anti-bacterial drug. -Alembic Pharma completes acquisition of Orit Laboratories. 2018 -Alembic Pharma gets USFDA nod for ophthalmic solution. -Alembic Pharma joint venture Aleor Dermaceuticals has received approval from the US health regulator for ointment which is used for temporary relief of pain. -Alembic Pharmaceuticals has received approval from the US health regulator to market Desenlafaxine extended-release tablets, used to treat major depressive disorder. -Alembic Pharma gets tentative USFDA nod for ophthalmic solution. -Alembic bags approval for Bupropion Hydrochloride Tablets. 2019 -Alembic Pharma gets USFDA final nod for Travoprost Ophthalmic Solution. -Alembic Pharma JV Aleor Dermaceuticals gets USFDA nod for plaque psoriasis treatment drug. - Alembic Pharma gets USFDA nod for intraocular pressure reduction drug. -Alembic Pharma gets USFDA nod for glaucoma treatment drug. 2020 -Alembic Pharma receives USFDA approval for Asenapine Sublingual Tablets. -Alembic Pharma gets final USFDA nod for eye drops solution. -Alembic Pharmaceuticals receives USFDA approval for ANDA Amantadine Hydrochloride Tablets. -Alembic gets USFDA nod for Vilazodone Hydrochloride tablets used to treat depression. -Alembic Pharma gets final USFDA nod for Fenofibrate tablets. 2021 -Alembic receives USFDA tentative approval for Selexipag Tablets. -Alembic Pharmaceuticals receives USFDA tentative approval for Dabigatran Etexilate Capsules. -Alembic Pharma gets USFDA nod for cancer treatment drug. -Alembic Pharmaceuticals has subscribed to partnership interest in ABCD Technologies LLP. 2022 -Alembic Pharmaceuticals receives USFDA approval for Cyclophosphamide Capsules. -Alembic Pharma gets USFDA nod for Entacapone tablets. -Alembic Pharmaceuticals gets US FDA nod for antibiotic drug. 2023 -Alembic has a cumulative total of 182 ANDA approvals from USFDA. 2024 -Alembic Pharmaceuticals has received USFDA approval for generic Divalproex Sodium delayed-release capsules, used in the treatment of epilepsy. -Alembic Pharmaceuticals has received USFDA approval for generic version of Paliperidone extended-release tablets indicated for the treatment of schizophrenia. - Alembic Pharmaceuticals has received USFDA approval for the abbreviated new drug application (ANDA) for Ivosidenib tablets of strength 250 mg

2011 Alembic Pharmaceuticals Limited ( the Resulting C ompany ) was originally incorporated on 16th June, 2010 in the name and style 'Alembic Pharma Limited', under the Companies Act, 1956 and had received the Certificate of Commencement of business on 1st July, 2010. The company changed its name from Alembic Pharma Limited to Alembic Pharmaceuticals Limited and the Registrar of Companies, Gujarat has approved the change of name and issued a fresh certificate of incorporation consequent upon change of name on 12th March, 2011. 2012 Alembic and Breckenridge Announce Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiqr). Alembic Pharmaceuticals Limited enters into a product development and license agreement with Accu-Break Pharmaceuticals, Inc, USA. 2013 -Alembic gets USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing agreement with Ranbaxy Pharmaceuticals Inc (Ranbaxy) to market its product in USA. 2014 -"Alembic announces joint venture with Adwiya Mami SARL Algeria through its wholly owned Subsidiary - Alembic Global Holding S.A.". 2015 -Alembic Pharmaceuticals Ltd. arm signs exclusive agreement with Novartis 2016 - Alembic Pharma inks JV agreement with Orbicular Pharma 2017 -Alembic Pharmaceuticals partners with Breckenridge Pharma launching tablets used in the treatment of major depressive disorder. -Alembic Pharma gets USFDA nod for generic antidepressant and anti-hypertension drugs. -Alembic gets FDA tentative nod for erectile dysfunction drug. -Alembic Pharma gets USFDA nod for anti-bacterial drug. -Alembic Pharma completes acquisition of Orit Laboratories. 2018 -Alembic Pharma gets USFDA nod for ophthalmic solution. -Alembic Pharma joint venture Aleor Dermaceuticals has received approval from the US health regulator for ointment which is used for temporary relief of pain. -Alembic Pharmaceuticals has received approval from the US health regulator to market Desenlafaxine extended-release tablets, used to treat major depressive disorder. -Alembic Pharma gets tentative USFDA nod for ophthalmic solution. -Alembic bags approval for Bupropion Hydrochloride Tablets. 2019 -Alembic Pharma gets USFDA final nod for Travoprost Ophthalmic Solution. -Alembic Pharma JV Aleor Dermaceuticals gets USFDA nod for plaque psoriasis treatment drug. - Alembic Pharma gets USFDA nod for intraocular pressure reduction drug. -Alembic Pharma gets USFDA nod for glaucoma treatment drug. 2020 -Alembic Pharma receives USFDA approval for Asenapine Sublingual Tablets. -Alembic Pharma gets final USFDA nod for eye drops solution. -Alembic Pharmaceuticals receives USFDA approval for ANDA Amantadine Hydrochloride Tablets. -Alembic gets USFDA nod for Vilazodone Hydrochloride tablets used to treat depression. -Alembic Pharma gets final USFDA nod for Fenofibrate tablets. 2021 -Alembic receives USFDA tentative approval for Selexipag Tablets. -Alembic Pharmaceuticals receives USFDA tentative approval for Dabigatran Etexilate Capsules. -Alembic Pharma gets USFDA nod for cancer treatment drug. -Alembic Pharmaceuticals has subscribed to partnership interest in ABCD Technologies LLP. 2022 -Alembic Pharmaceuticals receives USFDA approval for Cyclophosphamide Capsules. -Alembic Pharma gets USFDA nod for Entacapone tablets. -Alembic Pharmaceuticals gets US FDA nod for antibiotic drug. 2023 -Alembic has a cumulative total of 182 ANDA approvals from USFDA. 2024 -Alembic Pharmaceuticals has received USFDA approval for generic Divalproex Sodium delayed-release capsules, used in the treatment of epilepsy. -Alembic Pharmaceuticals has received USFDA approval for generic version of Paliperidone extended-release tablets indicated for the treatment of schizophrenia. - Alembic Pharmaceuticals has received USFDA approval for the abbreviated new drug application (ANDA) for Ivosidenib tablets of strength 250 mg

Read More

Parent Organisation

Alembic Pharmaceuticals Ltd.

Founded

16/06/2010

Managing Director

Mr.Chirayu Amin

NSE Symbol

APLLTDEQ

FAQ

The current price of Alembic Pharmaceuticals Ltd is ₹ 827.35.

The 52-week high for Alembic Pharmaceuticals Ltd is ₹ 836.00 and the 52-week low is ₹ 800.25.

The market capitalization of Alembic Pharmaceuticals Ltd is currently ₹ 16262.65. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Alembic Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Alembic Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Alembic Pharmaceuticals Ltd shares.

The CEO of Alembic Pharmaceuticals Ltd is Mr.Chirayu Amin, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT